Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II

NCT03751761 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT03751761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03751761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Lead sponsor
Asan Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
June 11, 2018
Completion date
August 30, 2023
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric cancer